Coronaviruses and other Novel Antiviral Targets

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as the Program Director for UMBC’s Chemistry-Biology Interface graduate training program funded by NIH since 2007. This program promotes hands on cross disciplinary research for almost 50 PhD students from four departments at UMBC and UMB. She is currently the Immediate Past President and Secretary-Elect for the International Society of Nucleosides, Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy, Molecules – Chemical Biology, and Current Protocols in Chemical Biology.

1. Improving properties of the nucleobase analogs T-705/T-1105 as potential antivirals

2. Anno 2021: Which antivirals for the coming decade?

3. Broad spectrum antiviral fleximer nucleosides

4. The search for antivirals to treat alphavirus infections

5. Inhibitors of Ebola Virus targeting Innate immune evasion

6. Uracil derivatives as non-nucleoside inhibitors of viral infections